Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Evanthia T. Roussos Torres"'
Autor:
Katherine E. Lake, Megan M. Colonnetta, Clayton A. Smith, Kaitlyn Saunders, Kenneth Martinez-Algarin, Sakshi Mohta, Jacob Pena, Heather L. McArthur, Sangeetha M. Reddy, Evanthia T. Roussos Torres, Elizabeth H. Chen, Isaac S. Chan
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Breast cancer metastases exhibit many different genetic alterations, including copy number amplifications (CNA). CNA are genetic alterations that are increasingly becoming relevant to breast oncology clinical practice. Here we identify CNA in metasta
Externí odkaz:
https://doaj.org/article/6dc288cfdc534f16a59861efad05a650
Autor:
Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Evanthia T. Roussos Torres
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune
Externí odkaz:
https://doaj.org/article/8b0d35ab3ce5400f8a02d8f094918d24
Autor:
Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David Tuck, Nathanael Fillmore, Nicolas A. Giraldo, Michael Topper, Stephen Baylin, Marc Lippman, Claudine Isaacs, Reva Basho, Ilya Serebriiskii, Heinz-Josef Lenz, Igor Astsaturov, John Marshall, Josephine Taverna, Jerry Lee, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani Weeraratna, Hariharan Easwaran, Elana J. Fertig
Publikováno v:
Cell Reports, Vol 37, Iss 7, Pp 110033- (2021)
Externí odkaz:
https://doaj.org/article/1929927bbd9e4b6ca3ee96700e38831f
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-relat
Externí odkaz:
https://doaj.org/article/f7a4ccdbc3fa444e9ff615ce7141361e
Autor:
Hanwen Wang, Richard J. Sové, Mohammad Jafarnejad, Sondra Rahmeh, Elizabeth M. Jaffee, Vered Stearns, Evanthia T. Roussos Torres, Roisin M. Connolly, Aleksander S. Popel
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
The survival rate of patients with breast cancer has been improved by immune checkpoint blockade therapies, and the efficacy of their combinations with epigenetic modulators has shown promising results in preclinical studies. In this prospective stud
Externí odkaz:
https://doaj.org/article/cb64f5ecdaba4c1e956194ff56dcf3b4
Autor:
Adam C. Mirando, Akash Patil, Christine I. Rafie, Brian J. Christmas, Niranjan B. Pandey, Vered Stearns, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Aleksander S. Popel
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following
Externí odkaz:
https://doaj.org/article/d7ce52b28cfc47f195f57a6014ece82b
Publikováno v:
Cancer Research. 83:P6-10
Pharmacological Strategies to Target Circadian Clock Genes in TNBC Yuanzhong Pan, Priya Jayachandran, Evanthia T. Roussos Torres, Steve A. Kay Background: Triple-negative breast cancer (TNBC) remains the most aggressive form of breast cancer and more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d86eb5829d6c0b11053735dc7a04187
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-17
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-17
Autor:
Priya Jayachandran, Yasmine Baca, Joanne Xiu, Yuanzhong Pan, Phil Walker, Francesca Battaglin, Hiroyuki Arai, Moh’d Khushman, Janice Lu, Darcy Spicer, Shannon Mumenthaler, Richard Goldberg, Benjamin Weinberg, Emil Lou, Michael Hall, Arielle L. Heeke, W. Michael Korn, Steve A. Kay, Heinz-Josef Lenz, Evanthia T. Roussos Torres
Publikováno v:
Cancer Research. 83:P4-08
Background: Disruption of circadian processes has been linked to cancer initiation, progression, metastasis, resistance, and mortality. Clock proteins are an emerging target for therapy in breast cancer. Circadian rhythms are controlled by a network
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9610eb5d29863e7b6bc0981f90fbbc5
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-06
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-06
Autor:
Priya Jayachandran, Francesca Battaglin, Carly Strelez, Annika Lenz, Sandra Algaze, Shivani Soni, Jae Ho Lo, Yan Yang, Joshua Millstein, Wu Zhang, Jean C. Shih, Janice Lu, Shannon M. Mumenthaler, Darcy Spicer, Josh Neman, Evanthia T. Roussos Torres, Heinz-Josef Lenz
Publikováno v:
Oncogene. 42:627-637
Exploring the relationship between various neurotransmitters and breast cancer cell growth has revealed their likely centrality to improving breast cancer treatment. Neurotransmitters play a key role in breast cancer biology through their effects on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8be946c3a46f7fb9c26c3f4e1a24493
https://doi.org/10.1038/s41388-022-02584-4
https://doi.org/10.1038/s41388-022-02584-4
Autor:
Whitney L. Hensing, Joanne Xiu, W. Michael Korn, Stephanie L. Graff, Irene Kang, Evanthia T. Roussos Torres, Arielle L. Heeke, Andrew A. Davis, Nusayba A. Bagegni, Katherine K. Clifton, Ron Bose, Cynthia Ma, Foluso O. Ademuyiwa
Publikováno v:
Cancer Research. 83:P3-05
Introduction: Estrogen receptor (ER) loss occurs in about 20% of recurrent breast cancers (BC) and is associated with unresponsiveness to endocrine therapy (ET) and poor prognosis. Prior studies evaluating ER-loss included predominately patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5bcb7bc3af3f89462dd933887a3c847
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-08
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-08